drugset / Trial / NCT04961541
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this combination is referred to as ICC vaccine.
Timeline
- Start
- 2021-09-08
- Primary completion
- 2021-12-22
- Completion
- 2022-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Matrix-M1 | Other / unclassified | 50 ug | Intramuscular |
| Subject | Matrix-M1 | Other / unclassified | 75 ug | Intramuscular |
| Subject | SARS-CoV-2 rS | Vaccine | 5 ug | Intramuscular |
| Subject | qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant | Vaccine | 60 ug | Intramuscular |